Terns acquires NASH compounds from Eli Lilly

Terns Pharmaceuticals Inc. (San Mateo, Calif.) gained exclusive, worldwide rights to develop and commercialize three small molecule non-alcoholic steatohepatitis candidates from Eli Lilly and Co. (NYSE:LLY). The partners declined to disclose financial terms.

Terns will initially focus on developing the candidates in China...